In summary, we demonstrated that EGFR internalization is associated with resistance to cetuximab therapy in CRC and that this relationship can be pharmacologically modulated to improve the effectiveness of EGFR‐targeted therapy in CRCs. This evidence concerns the gene EGFR and colorectal carcinoma.